Skip to main content
Top
Published in: Annals of Surgical Oncology 2/2015

01-02-2015 | Bone and Soft Tissue Sarcomas

Improved Survival in Osteosarcoma Patients with Atypical Low Vascularization

Authors: Pierre Kunz, Joerg Fellenberg, Linda Moskovszky, Zoltan Sápi, Tibor Krenacs, Isidro Machado, Johannes Poeschl, Burkhard Lehner, Miklos Szendrõi, Peter Ruef, Michael Bohlmann, Antonio Llombart Bosch, Volker Ewerbeck, Ralf Kinscherf, Benedikt Fritzsching

Published in: Annals of Surgical Oncology | Issue 2/2015

Login to get access

Abstract

Background

Osteosarcoma is considered a highly vascularized bone tumor with early metastatic dissemination through intratumoral blood vessels mostly into the lung. Novel targets for therapy such as tumor vascularization are highly warranted since little progress has been achieved in the last 30 years. However, proof of relevance for vascularization as a major prognostic parameter has been hampered by tumor heterogeneity, difficulty in detecting microvessels by immunohistochemistry, and small study cohorts. Most recently, we demonstrated that highly standardized whole-slide imaging could overcome these limitations (Kunz et al., PloS One 9(3):e90727, 2014). In this study, we applied this method to a multicenter cohort of 131 osteosarcoma patients to test osteosarcoma vascularization as a prognostic determinant.

Methods

Computer-assisted whole-slide analysis, together with enzymatic epitope retrieval, was used for CD31-based microvessel quantification in 131 pretreatment formalin-fixed and paraffin-embedded biopsies from three bone tumor centers. Kaplan–Meier-estimated survival and chemoresponse were determined and multivariate analysis was performed. Conventional hot-spot-based microvessel density (MVD) determination was compared with whole-slide imaging.

Results

We detected high estimated overall (p ≤ 0.008) and relapse-free (p ≤ 0.004) survival in 25 % of osteosarcoma patients with low osteosarcoma vascularization in contrast to other patient groups. Furthermore, all patients with low osteosarcoma vascularization showed a good response to neoadjuvant chemotherapy. Comparison of conventional MVD determination with whole-slide imaging suggests false high quantification or even exclusion of samples with low osteosarcoma vascularization due to difficult CD31 detection in previous studies.

Conclusion

Low intratumoral vascularization at the time of diagnosis is a strong predictor for prolonged survival and good response to neoadjuvant chemotherapy in osteosarcoma.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kunz P, Fellenberg J, Moskovszky L, et al. Osteosarcoma microenvironment: whole-slide imaging and optimized antigen detection overcome major limitations in immunohistochemical quantification. PloS One. 2014;9(3):e90727.PubMedCentralPubMedCrossRef Kunz P, Fellenberg J, Moskovszky L, et al. Osteosarcoma microenvironment: whole-slide imaging and optimized antigen detection overcome major limitations in immunohistochemical quantification. PloS One. 2014;9(3):e90727.PubMedCentralPubMedCrossRef
2.
go back to reference Dishop MK, Kuruvilla S. Primary and metastatic lung tumors in the pediatric population: a review and 25-year experience at a large children’s hospital. Arch Pathol Lab Med. 2008;132(7):1079–1103.PubMed Dishop MK, Kuruvilla S. Primary and metastatic lung tumors in the pediatric population: a review and 25-year experience at a large children’s hospital. Arch Pathol Lab Med. 2008;132(7):1079–1103.PubMed
3.
go back to reference Ek ET, Ojaimi J, Kitagawa Y, Choong PF. Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma? Oncol Rep. 2006;16(1):17–23.PubMed Ek ET, Ojaimi J, Kitagawa Y, Choong PF. Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma? Oncol Rep. 2006;16(1):17–23.PubMed
4.
go back to reference Ek ET, Ojaimi J, Kitagawa Y, Choong PF. Outcome of patients with osteosarcoma over 40 years of age: is angiogenesis a marker of survival? Int Semin Surg Oncol. 2006;3:7.PubMedCentralPubMedCrossRef Ek ET, Ojaimi J, Kitagawa Y, Choong PF. Outcome of patients with osteosarcoma over 40 years of age: is angiogenesis a marker of survival? Int Semin Surg Oncol. 2006;3:7.PubMedCentralPubMedCrossRef
5.
go back to reference Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000;6(2):572–577.PubMed Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000;6(2):572–577.PubMed
6.
go back to reference Kreuter M, Bieker R, Bielack SS, et al. Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res. 2004;10(24):8531–8537.PubMedCrossRef Kreuter M, Bieker R, Bielack SS, et al. Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res. 2004;10(24):8531–8537.PubMedCrossRef
7.
go back to reference Mantadakis E, Kim G, Reisch J, et al. Lack of prognostic significance of intratumoral angiogenesis in nonmetastatic osteosarcoma. J Pediatr Hematol Oncol. 2001;23(5):286–289.PubMedCrossRef Mantadakis E, Kim G, Reisch J, et al. Lack of prognostic significance of intratumoral angiogenesis in nonmetastatic osteosarcoma. J Pediatr Hematol Oncol. 2001;23(5):286–289.PubMedCrossRef
8.
go back to reference Mikulic D, Ilic I, Cepulic M, et al. Tumor angiogenesis and outcome in osteosarcoma. Pediatr Hematol Oncol. 2004;21(7):611–619.PubMedCrossRef Mikulic D, Ilic I, Cepulic M, et al. Tumor angiogenesis and outcome in osteosarcoma. Pediatr Hematol Oncol. 2004;21(7):611–619.PubMedCrossRef
9.
go back to reference Oda Y, Yamamoto H, Tamiya S, et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol. 2006;19(5):738–745.PubMedCrossRef Oda Y, Yamamoto H, Tamiya S, et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol. 2006;19(5):738–745.PubMedCrossRef
10.
go back to reference Sorensen FB, Jensen K, Vaeth M, et al. Immunohistochemical estimates of angiogenesis, proliferative activity, p53 expression, and multiple drug resistance have no prognostic impact in osteosarcoma: a comparative clinicopathological investigation. Sarcoma. 2008;2008:874075.PubMedCentralPubMedCrossRef Sorensen FB, Jensen K, Vaeth M, et al. Immunohistochemical estimates of angiogenesis, proliferative activity, p53 expression, and multiple drug resistance have no prognostic impact in osteosarcoma: a comparative clinicopathological investigation. Sarcoma. 2008;2008:874075.PubMedCentralPubMedCrossRef
11.
go back to reference Yang QC, Zeng BF, Dong Y, Shi ZM, Jiang ZM, Huang J. Overexpression of hypoxia-inducible factor-1alpha in human osteosarcoma: correlation with clinicopathological parameters and survival outcome. Jpn J Clin Oncol. 2007;37(2):127–134.PubMedCrossRef Yang QC, Zeng BF, Dong Y, Shi ZM, Jiang ZM, Huang J. Overexpression of hypoxia-inducible factor-1alpha in human osteosarcoma: correlation with clinicopathological parameters and survival outcome. Jpn J Clin Oncol. 2007;37(2):127–134.PubMedCrossRef
12.
go back to reference Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 2008;134(3):281–297.PubMedCrossRef Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 2008;134(3):281–297.PubMedCrossRef
13.
go back to reference Hogendoorn PC, Athanasou N, Bielack S, et al. Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v204–213.PubMedCrossRef Hogendoorn PC, Athanasou N, Bielack S, et al. Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v204–213.PubMedCrossRef
14.
go back to reference Iwata S, Ishii T, Kawai A, et al. Prognostic factors in elderly osteosarcoma patients: a multi-institutional retrospective study of 86 cases. Ann Surg Oncol. 2014;21(1):263–268.PubMedCrossRef Iwata S, Ishii T, Kawai A, et al. Prognostic factors in elderly osteosarcoma patients: a multi-institutional retrospective study of 86 cases. Ann Surg Oncol. 2014;21(1):263–268.PubMedCrossRef
15.
go back to reference Okada K, Hasegawa T, Nishida J, et al. Osteosarcomas after the age of 50: a clinicopathologic study of 64 cases–an experience in northern Japan. Ann Surg Oncol. 2004;11(11):998–1004.PubMedCrossRef Okada K, Hasegawa T, Nishida J, et al. Osteosarcomas after the age of 50: a clinicopathologic study of 64 cases–an experience in northern Japan. Ann Surg Oncol. 2004;11(11):998–1004.PubMedCrossRef
16.
go back to reference Xu M, Xu CX, Bi WZ, et al. Effects of endostar combined multidrug chemotherapy in osteosarcoma. Bone. Nov 2013;57(1):111–115.PubMedCrossRef Xu M, Xu CX, Bi WZ, et al. Effects of endostar combined multidrug chemotherapy in osteosarcoma. Bone. Nov 2013;57(1):111–115.PubMedCrossRef
17.
go back to reference Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2002;20(3):776–790.PubMedCrossRef Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2002;20(3):776–790.PubMedCrossRef
18.
go back to reference Nathan SS, Healey JH. Demographic determinants of survival in osteosarcoma. Ann Acad Med Singapore. 2012;41(9):390–399.PubMed Nathan SS, Healey JH. Demographic determinants of survival in osteosarcoma. Ann Acad Med Singapore. 2012;41(9):390–399.PubMed
19.
go back to reference Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy – study COSS 80. J Cancer Res Clin Oncol. 1983;106 Suppl:21–24.PubMedCrossRef Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy – study COSS 80. J Cancer Res Clin Oncol. 1983;106 Suppl:21–24.PubMedCrossRef
20.
go back to reference Salzer-Kuntschik M, Brand G, Delling G. Determination of the degree of morphological regression following chemotherapy in malignant bone tumors [in German]. Der Pathologe. 1983;4(3):135–141.PubMed Salzer-Kuntschik M, Brand G, Delling G. Determination of the degree of morphological regression following chemotherapy in malignant bone tumors [in German]. Der Pathologe. 1983;4(3):135–141.PubMed
21.
go back to reference Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980(153):106–120.PubMed Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980(153):106–120.PubMed
22.
go back to reference Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1–8.PubMedCrossRef Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1–8.PubMedCrossRef
23.
go back to reference Hara H, Akisue T, Fujimoto T, et al. Expression of VEGF and its receptors and angiogenesis in bone and soft tissue tumors. Anticancer Res. 2006;26(6B):4307–4311.PubMed Hara H, Akisue T, Fujimoto T, et al. Expression of VEGF and its receptors and angiogenesis in bone and soft tissue tumors. Anticancer Res. 2006;26(6B):4307–4311.PubMed
24.
go back to reference Chen D, Zhang YJ, Zhu KW, Wang WC. A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma. Tumour Biol. 2013;34(3):1895–1899.PubMedCrossRef Chen D, Zhang YJ, Zhu KW, Wang WC. A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma. Tumour Biol. 2013;34(3):1895–1899.PubMedCrossRef
25.
go back to reference Qu JT, Wang M, He HL, Tang Y, Ye XJ. The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review. J Cancer Res Clin Oncol. 2012;138(5):819–825.PubMedCrossRef Qu JT, Wang M, He HL, Tang Y, Ye XJ. The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review. J Cancer Res Clin Oncol. 2012;138(5):819–825.PubMedCrossRef
26.
go back to reference Chen P, Wang SJ, Wang HB, et al. The distribution of IGF2 and IMP3 in osteosarcoma and its relationship with angiogenesis. J Mol Histol. 2012;43(1):63–70.PubMedCrossRef Chen P, Wang SJ, Wang HB, et al. The distribution of IGF2 and IMP3 in osteosarcoma and its relationship with angiogenesis. J Mol Histol. 2012;43(1):63–70.PubMedCrossRef
27.
go back to reference Chen Z, Chen QX, Hou ZY, Hu J, Cao YG. Clinical predictive value of serum angiogenic factor in patients with osteosarcoma. Asian Pac J Cancer Prev. 2012;13(9):4823–4826.PubMedCrossRef Chen Z, Chen QX, Hou ZY, Hu J, Cao YG. Clinical predictive value of serum angiogenic factor in patients with osteosarcoma. Asian Pac J Cancer Prev. 2012;13(9):4823–4826.PubMedCrossRef
28.
go back to reference Lammli J, Fan M, Rosenthal HG, et al. Expression of vascular endothelial growth factor correlates with the advance of clinical osteosarcoma. Int Orthop. 2012;36(11):2307–2313.PubMedCentralPubMedCrossRef Lammli J, Fan M, Rosenthal HG, et al. Expression of vascular endothelial growth factor correlates with the advance of clinical osteosarcoma. Int Orthop. 2012;36(11):2307–2313.PubMedCentralPubMedCrossRef
29.
go back to reference Rossi B, Schinzari G, Maccauro G, et al. Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis. BMC Musculoskelet Disord. 2010;11:34.PubMedCentralPubMedCrossRef Rossi B, Schinzari G, Maccauro G, et al. Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis. BMC Musculoskelet Disord. 2010;11:34.PubMedCentralPubMedCrossRef
30.
go back to reference Fox SB, Leek RD, Smith K, Hollyer J, Greenall M, Harris AL. Tumor angiogenesis in node-negative breast carcinomas–relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat. 1994;29(1):109–116.PubMedCrossRef Fox SB, Leek RD, Smith K, Hollyer J, Greenall M, Harris AL. Tumor angiogenesis in node-negative breast carcinomas–relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat. 1994;29(1):109–116.PubMedCrossRef
31.
go back to reference Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer. 2002;38(12):1564–1579.PubMedCrossRef Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer. 2002;38(12):1564–1579.PubMedCrossRef
32.
go back to reference Gronchi A, Miceli R, Colombo C, et al. Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution. Ann Oncol. 2011;22(7):1675–1681.PubMedCrossRef Gronchi A, Miceli R, Colombo C, et al. Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution. Ann Oncol. 2011;22(7):1675–1681.PubMedCrossRef
33.
go back to reference Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn’t tell us. J Natl Cancer Inst. 2002;94(12):883–893.PubMedCrossRef Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn’t tell us. J Natl Cancer Inst. 2002;94(12):883–893.PubMedCrossRef
Metadata
Title
Improved Survival in Osteosarcoma Patients with Atypical Low Vascularization
Authors
Pierre Kunz
Joerg Fellenberg
Linda Moskovszky
Zoltan Sápi
Tibor Krenacs
Isidro Machado
Johannes Poeschl
Burkhard Lehner
Miklos Szendrõi
Peter Ruef
Michael Bohlmann
Antonio Llombart Bosch
Volker Ewerbeck
Ralf Kinscherf
Benedikt Fritzsching
Publication date
01-02-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 2/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-4001-2

Other articles of this Issue 2/2015

Annals of Surgical Oncology 2/2015 Go to the issue